User login

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
9 + 0 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.

RESSTORE: a Multicentric and European clinical trial 2015-2020

RESSTORE, REgenerative Stem cell therapy for STroke in Europe, is a multicentric project in Personalising health and care (PHC) area financed by the European Commission H2020 programme. The RESSTORE project is focused on the assessment of the efficacy of intravenous cell therapy to improve recovery and/or compensation after ischemic stroke. The RESSTORE consortium consists of 28 partners, including 23 clinical centers, 5 cell therapy units, 5 experimental laboratories, 1 Clinical Research Organisation. The project, co-coordinated by Dr Olivier Detante (CHU Grenoble, France) and Pr Exuperio DIEZ TEJEDOR (SERMAS, Madrid, Spain), will recruit 400 patients from the Czech Republic, Finland, France, Spain, Scotland and deliver new knowledge on the fast growing area of regenerative medicine. The project started in September 2015 and will receive funding from the European Commission for 5 years.

Disclaimer: The RESSTORE project and associated cell therapy is an experimental study with a well defined scientific scope which adheres to the most stringent regulatory and ethical requirements. Patient recruitment follows a strict procedure (inclusion/exclusion criteria according to a large range of variables), applied by clinical experts in all partnering centres to meet the boundaries defined in the study protocol. 

The RESSTORE cellular therapy is (as one of the major inclusion criterias amongst several others) specifically targeted to individuals who suffered from a particular type of stroke (hemispheric, ischemic stroke) and who can be enroled in the study after 1-4 days post-stroke

NCT number: NCT02849613 and EudraCT number: 2016-001902-40

Latest news

RESSTORE clinical meeting - Prague

First RESSTORE progress meeting

The first RESSTORE progress meeting took place on the 6th and 7th of October 2016 in the Chateau de Montchât, in Lyon (France). This event allowed partners to follow all current ongoing activities on the project, review in-depth the clinical trial protocol with the input of expert clinicians as well as discuss any potential bottlenecks that should be overcome. The project is on track - all authorisations required to launch the clinical trial are being gathered while all necessary links between all participating clinical centers, cell manufacturing groups and Medfiles -the CRO in charge of all operationnel aspects of the trial - are now in place.

RESSTORE Twitter account online

The RESSTORE Twitter account (@RESSTORE_CT) was recently created to act as a relay for all the news related to the project ecosystem. Please follow us for some up-to-date news on the trial and spread the word about the impact of Stroke as well as ongoing initiatives to assist patients and their families in their daily batlle. 

Agenda

25th European Society of Gene and Cell Therapy

Tuesday, October 17, 2017 to Friday, October 20, 2017

We are happy to announce that the 25th Anniversary Congress of the ESGCT will take place in Berlin, Germany, at the bcc Berlin, in collaboration with the German Society for Gene Therapy DG-GT. For more information: http://www.esgct.eu/Congress.aspx

47th SFN annual meeting

Saturday, November 11, 2017 to Wednesday, November 15, 2017

SfN’s 47th annual meeting, Neuroscience 2017, is the world’s largest neuroscience conference for scientists and physicians devoted to understanding the brain and nervous system.